Clinical Trial

Sleep Trial to Prevent Alzheimer's Disease

Study acronym: SToP-AD
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine if treatment with the sleep aid suvorexant can decrease the rate of amyloid-β (Aβ) accumulation in the brain.
Protocol Amendment History 2 changes
notable Sponsor changed: Washington University School of Medicine -> University of Minnesota 2026-07-14
notable Enrollment reduced: 200 -> 120 participants 2026-07-01
Trial Details
NCT Number NCT04629547
Lead Sponsor University of Minnesota
Collaborators: Good Ventures, Merck Sharp & Dohme LLC
Conditions Sleep, Alzheimer Disease
Enrollment 120 participants
Start Date 2022-05-25
Primary Completion 2028-05 (estimated)
Study Completion 2028-05 (estimated)
Updated on ClinicalTrials.gov 2026-07-13